Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cell of Origin Predicts Outcome to Treatment with Etoposide-containing Chemotherapy in Young Patients with High-risk Diffuse Large B-cell Lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. No association between early maternal HbA1c and offspring birthweight among women without pre-existing diabetes in Greenland

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Joint tobacco smoking and alcohol intake exacerbates cancer risk in women- the Danish nurse cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Abstract Addition of etoposide to the R-CHOP chemotherapy-regimen with cyclofosfamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOEP), has resulted in improved survival in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). It is not known if biological factors can predict this effect. In this study 245 patients representing all young patients with high-risk DLBCL treated with R-CHOP or R-CHOEP in 2004-2012 in Denmark, were extracted from the Danish lymphoma database. Patients were stratified according to cell-of-origin (COO) into germinal-center B-cell-like (GCB) or nonGCB by Hans algorithm. Only in patients with GCB phenotype was treatment with R-CHOEP associated with improved progression free survival (PFS) and overall survival (OS) compared with R-CHOP. Patients with GCB phenotype treated with R-CHOEP also had superior OS compared with patients with nonGCB phenotype treated with R-CHOEP. This was not seen in R-CHOP treated patients. This could suggest that R-CHOEP should be restricted to patients with GCB phenotype.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind56
Udgave nummer7
Sider (fra-til)2039-2046
ISSN1042-8194
DOI
StatusUdgivet - 2015

ID: 44861584